In developing new drugs for rare diseases, this non-profit steps in when pharmaceutical companies won’t
ABCNews.com, 1/5/19
–In developing new drugs for rare diseases, this non-profit steps in when pharmaceutical companies won’t
This piece highlights Stanford’s fast-growing drug-development program SPARK, which has given hundreds of academic researchers around the world the training and connections to get their discoveries out of labs and into the hands of doctors and patients. Daria Mochly-Rosen, the George D. Smith Professor in Translational Medicine and founder of SPARK; Kevin Grimes, professor of chemical and systems biology; and Roham Zamanian, associate professor of medicine, are quoted here.